SUBCUTANEOUS RECOMBINANT-HUMAN-ERYTHROPOIETIN IN CHILDREN WITH RENAL ANEMIA ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS

被引：6

作者：

AUFRICHT, C ^{[1
]}

BALZAR, E ^{[1
]}

STEGER, H ^{[1
]}

LOTHALLER, MA ^{[1
]}

FRENZEL, K ^{[1
]}

KOHLHAUSER, C ^{[1
]}

KISS, H ^{[1
]}

KHOSS, AE ^{[1
]}

KERNOVA, T ^{[1
]}

机构：

[1] UNIV VIENNA, DEPT PEDIAT, A-1010 VIENNA, AUSTRIA

来源：

ACTA PAEDIATRICA | 1993年 / 82卷 / 11期

关键词：

ERYTHROPOIETIN CHILDREN; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS;

D O I：

10.1111/j.1651-2227.1993.tb12608.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Subcutaneous recombinant human erythropoietin (rHuEpo) treatment of renal anemia was performed in four boys and eight girls on CAPD, aged 0.8-12.5 (mean 7.4) years. In contrast to previous studies, our therapeutic goal was not set with a hematocrit of 30% but with full correction of anemia. Following a maximum weekly rHuEpo dosage of median 120 (range 100 240) IU/kg body weight, hematocrit increased in 10 children from 24 (14-29)% within 12 (4-17) weeks to 40.1 (33.5-48.4)%. The weekly increase in hematocrit was 1.27 (0.5-3.1)%. The corrected reticulocyte count increased from 1.3 (0.7-1.8)% to 2.3 (1.4-3.9)% within 4 (2-6) weeks. Eight children fulfilled the protocol; six with an uncomplicated course were able to maintain a hematocrit of 37.1 (35.1-42.7)% with only one sc medication per week of approximately two-thirds of their highest weekly rHuEpo dosage. No serious adverse effect of rHuEpo therapy was observed.

引用

页码：959 / 962

页数：4

共 10 条

[1] EXERCISE TOLERANCE AFTER ANEMIA CORRECTION WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN END-STAGE RENAL-DISEASE [J].